Cellectis (NASDAQ:CLLS) Share Price Breaks Below Fifty Day Moving Average – Time to Sell?

Cellectis S.A. (NASDAQ:CLLS)’s stock price passed below its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $2.49 and traded as low as $1.2205. Cellectis shares last traded at $1.25, with a volume of 106,832 shares traded.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on CLLS shares. Robert W. Baird reduced their target price on shares of Cellectis from $10.00 to $8.00 and set an “outperform” rating for the company in a research note on Tuesday, September 15th. Barclays cut shares of Cellectis from an “overweight” rating to an “underweight” rating and lowered their target price for the stock from $9.00 to $1.30 in a report on Wednesday, September 16th. Weiss Ratings raised shares of Cellectis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 2nd. Wells Fargo & Company lowered their price objective on shares of Cellectis from $4.00 to $3.00 and set an “equal weight” rating for the company in a research report on Tuesday, September 15th. Finally, Citizens Jmp restated a “market perform” rating on shares of Cellectis in a research note on Tuesday, September 15th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $5.46.

Cellectis Trading Up 0.8%

The business’s 50 day simple moving average is $2.46 and its two-hundred day simple moving average is $3.05. The stock has a market cap of $126.43 million, a P/E ratio of -1.94 and a beta of 3.00. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 1.61.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings results on Friday, August 7th. The biotechnology company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.04. Cellectis had a negative return on equity of 94.19% and a negative net margin of 102.34%. The company had revenue of $6.90 million during the quarter, compared to analysts’ expectations of $11.05 million.

Hedge Funds Weigh In On Cellectis

An institutional investor recently bought a new position in Cellectis stock. Lido Advisors LLC purchased a new stake in shares of Cellectis S.A. (NASDAQ:CLLS) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 10,094 shares of the biotechnology company’s stock, valued at approximately $32,000. Hedge funds and other institutional investors own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis is a clinical-stage biotechnology company focused on developing gene-edited, allogeneic cell therapies for the treatment of cancer. The company uses its TALEN gene-editing technology to modify immune cells, including T cells, with the goal of creating “off-the-shelf” therapies that can be manufactured in advance and administered to multiple patients.

Cellectis’ development programs include UCART, or Universal Chimeric Antigen Receptor T-cell, therapies designed to target specific cancer antigens.